Drugs / Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells
Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells
Cell therapy targets CD19, CD22 via depletion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03398967 | Jan 2018 → May 2022 | lymphoid leukemia, lymphoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03398967 ↗ |
| Action | Deplete | “can recognize and kill the CD19 negative malignant cells” NCT03398967 ↗ |
| Modality | Cell therapy | “Universal CRISPR-Cas9 Gene-Editing CAR-T Cells” NCT03398967 ↗ |
| Route | Intravenous | “The CAR-T cells will be administered by i.v. injection over 20-30 minutes” NCT03398967 ↗ |
| Target | CD19 | “targeting CD19 and CD20 or CD22” NCT03398967 ↗ |
| Target | CD22 | “targeting CD19 and CD20 or CD22” NCT03398967 ↗ |